Full Text
Cost Effectiveness of Sunitinib as First-Line Targeted Therapy for Metastatic Renal Cell Carcinoma in China

Abstract

Authors

Q. Shi H. Yin J. Xuan Y. Wu G. Cheng

Back to Volume 17, Issue 7
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×